Associated Papers
Pharmacogenetics of First-Line Antitubercular Drugs: An Update.
Manca A et al.
Therapeutic Drug Monitoring, 2026
Polymorphisms of GSTM1, GSTT1, GSTP1 genes and chromosomal aberrations in lung cancer patients.
Minina VI et al.
Journal of Cancer Research and Clinical Oncology, 2017
Effect of gene-gene and gene-environment interactions associated with antituberculosis drug-induced hepatotoxicity.
Chamorro JG et al.
Pharmacogenetics and Genomics, 2017
N-acetyl transferase 2/environmental factors and their association as a modulating risk factor for sporadic colon and rectal cancer.
Procopciuc LM et al.
Journal of Clinical Laboratory Analysis, 2017
Factors associated with anti-TB drug-induced hepatotoxicity and genetic polymorphisms in indigenous and non-indigenous populations in Brazil.
Heinrich MM et al.
Tuberculosis (edinburgh, Scotland), 2016
NAT2 polymorphisms and risk for Parkinson's disease: a systematic review and meta-analysis.
Jiménez-Jiménez FJ et al.
Expert Opinion on Drug Metabolism & Toxicology, 2016
Genotype and allele frequencies of isoniazid-metabolizing enzymes NAT2 and GSTM1 in Latvian tuberculosis patients.
Igumnova V et al.
Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy, 2016
N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia.
Kamel AM et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine, 2015
Refinement of the prediction of N-acetyltransferase 2 (NAT2) phenotypes with respect to enzyme activity and urinary bladder cancer risk.
Selinski S et al.
Archives of Toxicology, 2013
Genetic variability in N-acetyltransferase 2 gene determines susceptibility to childhood lymphoid or myeloid leukemia in Brazil.
Zanrosso CW et al.
Leukemia & Lymphoma, 2012
Polymorphisms in heterocyclic aromatic amines metabolism-related genes are associated with colorectal adenoma risk.
Eichholzer M et al.
International Journal of Molecular Epidemiology and Genetics, 2012
Modulation of urinary polycyclic aromatic hydrocarbon metabolites by enzyme polymorphisms in workers of the German Human Bitumen Study.
Rihs HP et al.
Archives of Toxicology, 2011
A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background.
García-Closas M et al.
Pharmacogenetics and Genomics, 2011
GSTM1 null and NAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis.
Moore LE et al.
Carcinogenesis, 2011
Antioxidant enzymes, presbycusis, and ethnic variability.
Bared A et al.
Otolaryngology--head and Neck Surgery : Official Journal of American Academy of Otolaryngology-head and Neck Surgery, 2010
Genetic polymorphism in N-Acetyltransferase (NAT): Population distribution of NAT1 and NAT2 activity.
Walker K et al.
Journal of Toxicology and Environmental Health. Part B, Critical Reviews, 2009
Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.
Gresner P et al.
Lung Cancer (amsterdam, Netherlands), 2007
NAT2 slow acetylator genotype as an important modifier of breast cancer risk.
Sillanpää P et al.
International Journal of Cancer, 2005
Genotype and allele frequencies of TPMT, NAT2, GST, SULT1A1 and MDR-1 in the Egyptian population.
Hamdy SI et al.
British Journal of Clinical Pharmacology, 2003
Genetic susceptibility to breast cancer in French-Canadians: role of carcinogen-metabolizing enzymes and gene-environment interactions.
Krajinovic M et al.
International Journal of Cancer, 2001
N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review.
Brockton N et al.
American Journal of Epidemiology, 2000
[Genetic polymorphism in GST, NAT2, and MTRR and susceptibility to childhood acute leukemia].
Gra OA et al.
Molekuliarnaia Biologiia, 0